Datavault AI Grants Scilex Exclusive License for AI-Driven Biotech Exchange Platform

Datavault AI Inc. has granted Scilex Holding Company an exclusive worldwide license to deploy its proprietary AI-driven technology within the biotech and biopharma sectors. The agreement enables Scilex to build and operate a Biotech Exchange platform specifically designed to tokenize, trade, and monetize biotech assets including genomic data, diagnostics, and drug information. This strategic partnership represents a significant advancement in how biotechnology assets can be valued and exchanged using artificial intelligence and blockchain technology.

The financial terms of the agreement include a $10 million upfront payment structured in four installments, with potential milestone payments reaching up to $2.55 billion. This substantial financial commitment underscores the significant market potential both companies see in applying AI-driven blockchain solutions to the biotech industry. The technology is expected to expand beyond biotech into a comprehensive Pharmaceutical Exchange platform, addressing what Datavault AI estimates as a $2 trillion market opportunity.

The platform's ability to provide non-dilutive funding represents a transformative approach for biotech and pharmaceutical companies seeking capital. Traditional funding methods often require companies to dilute existing shareholder value through additional equity offerings. The tokenization approach enabled by Datavault AI's technology allows companies to monetize their assets without sacrificing ownership stakes, potentially revolutionizing how early-stage biotech companies secure necessary funding for research and development.

Datavault AI's technology portfolio includes the Information Data Exchange, which enables Digital Twins and licensing of name, image, and likeness by securely attaching physical real-world objects to immutable metadata objects. This technology foundation supports what the company describes as responsible AI with integrity, ensuring that sensitive biotech data and assets remain secure while being made available for commercial exchange. The company's cloud-based platform provides comprehensive solutions serving multiple industries, with high-performance computing expertise that supports the complex requirements of biotech data processing.

The exclusive license agreement leverages Datavault AI's broad patent portfolio, which includes foundational spatial and multichannel wireless HD sound transmission technologies through its Acoustic Science Division. While these audio technologies may seem unrelated to biotech applications, they demonstrate the company's expertise in developing sophisticated data transmission and processing systems that can be adapted across industries. The Data Science Division specifically focuses on leveraging Web 3.0 and high-performance computing to provide solutions for experiential data perception, valuation, and secure monetization.

For more information about Datavault AI's technology platform, visit https://www.datavaultsite.com. Additional news and updates relating to the company are available at https://ibn.fm/DVLT. The full press release detailing this exclusive licensing agreement can be accessed at https://ibn.fm/HAV6r.